10-K: Pasithea Therapeutics Corp. Files 2023 Annual Report, Highlights Clinical Progress and Strategic Focus

Pasithea Therapeutics Corp. released its 2023 annual report, detailing its shift to a therapeutics-focused company and progress in its clinical pipeline, particularly with PAS-004.

Summary

• Pasithea Therapeutics Corp. has transitioned to a clinical-stage biotechnology company focused on developing treatments for Central Nervous System (CNS) disorders and RASopathies.
• The company discontinued its clinics segment, including support services for anti-depression clinics in the UK and at-home services in New York, as well as clinical operations in Los Angeles.
• Pasithea's lead product candidate, PAS-004, a MEK inhibitor, received FDA clearance for a Phase 1 clinical trial, which is currently underway at four US sites with plans to expand to three sites in Eastern Europe.
• The company plans to advance PAS-004 into a Phase 1b/2 clinical trial for adult NF1-PN patients, followed by adolescent and pediatric patients.
• Other programs include PAS-003, a monoclonal antibody for ALS, and PAS-001, a small molecule for schizophrenia, both in earlier stages of development.
• The company completed a tender offer, repurchasing 266,171 shares of its common stock at $14.00 per share for a total of $3,726,416.
• As of December 31, 2023, Pasithea had cash and cash equivalents of approximately $16.3 million and an accumulated deficit of approximately $35.3 million.
• The company reported a net loss of approximately $16.0 million for the year ended December 31, 2023, compared to a net loss of $13.9 million in 2022.
• Research and development expenses increased to $8.1 million in 2023 from $2.7 million in 2022, primarily due to the clinical development of PAS-004.
• General and administrative expenses decreased to $7.9 million in 2023 from $9.9 million in 2022, due to non-recurring costs in 2022.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical development and a clear strategic focus, the company's financial position is weak, with significant losses and a need for additional capital. The company also has a material weakness in its internal controls. This suggests a cautious outlook from an investment perspective.

Positives

• FDA clearance for PAS-004 Phase 1 clinical trial indicates regulatory progress.
• Advancement of PAS-004 into Phase 1b/2 trials for NF1-PN patients demonstrates a clear clinical development plan.
• The company has a pipeline of three therapeutic product candidates, including PAS-004, PAS-003, and PAS-001.
• The company has completed GMP-compliant manufacturing of PAS-004 for its Phase 1 clinical trial.
• The company has a clear strategy to seek business development and collaborative opportunities for its discovery programs.
• The company has a strong scientific advisory board.
• The company has a clear strategy to seek business development and collaborative opportunities for its discovery programs.

Negatives

• The company has a history of operating losses and expects to continue to incur substantial costs.
• The company is not currently profitable and may never achieve or sustain profitability.
• The company will need to raise additional capital to complete the development and commercialization of its product candidates.
• The company is dependent on the successful development and commercialization of PAS-004, which is not yet approved.
• The company relies on third parties to conduct clinical trials and manufacture its product candidates.
• The company has a limited operating history and has not generated any material revenue from product sales.
• The company has identified a material weakness in its internal control over financial reporting related to certain tax disclosures.

Risks

• The company has a limited operating history and has not generated any material revenue from product sales.
• The company has a history of losses and may not be able to achieve profitability going forward.
• The company will require additional capital to fund its operations, and if it fails to obtain necessary financing, it may not be able to complete the development and commercialization of its drugs.
• Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.
• The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable.
• The company relies on third parties to conduct its clinical trials and its regulatory submissions for its product candidates.
• The company is increasingly dependent on information technology, and its systems and infrastructure face certain risks, including cybersecurity and data leakage risks.
• If the company's intellectual property related to its products or product candidates is not adequate, it may not be able to compete effectively in its market.
• An active trading market for the company's Common Stock or warrants may not be sustained.
• The company may be subject to securities litigation, which is expensive and could divert management attention.

Future Outlook

The company expects research and development expenses to increase in fiscal year 2024 due to the clinical development of PAS-004 and related CMC activities. The company also expects general and administrative expenses to decrease in fiscal year 2024 due to non-recurring expenses incurred in 2023.

Management Comments

• Management believes that the company will not have sufficient working capital to meet its needs through twelve months from the date of these financial statements if additional funding cannot be obtained.
• Management believes that the use of contract CMOs eliminates the need to directly invest in manufacturing facilities, equipment and additional staff.

Industry Context

The company operates in the competitive biotechnology and pharmaceutical industries, facing competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic and research institutions. The company is focused on developing innovative therapies to address areas of high unmet medical need, initially in RASopathies and CNS disorders.

Comparison to Industry Standards

• Pasithea's approach to developing a next-generation MEK inhibitor, PAS-004, is in line with industry trends of targeting the MAPK pathway for various diseases, including RASopathies and cancers. Companies like GSK, Pfizer, and AstraZeneca have already received FDA approval for MEK inhibitors, but Pasithea aims to address the limitations of these earlier generation drugs.
• The company's focus on CNS disorders, particularly ALS and schizophrenia, aligns with the industry's growing interest in developing treatments for these challenging conditions. Several companies are actively pursuing novel therapies for ALS, including Biogen and Amylyx Pharmaceuticals, while others are exploring new approaches for schizophrenia, such as those targeting inflammatory pathways.
• Pasithea's strategy of seeking business development and collaborative opportunities is a common practice in the biotechnology industry, particularly for companies with limited resources. This approach allows companies to leverage the expertise and resources of larger pharmaceutical organizations to accelerate the development and commercialization of their product candidates.
• The company's decision to discontinue its clinics segment and focus on therapeutics development is a strategic move that aligns with the industry's trend of specialization and focus on core competencies. This allows the company to allocate its resources more efficiently and focus on its core strength in drug discovery and development.

Related Party Transactions

• The company entered into a contract with PsychoGenics, Inc. for the conduct of one of its preclinical studies. Dr. Emer Leahy, a member of the company's Board, is the current Chief Executive Officer and a less than 5% owner of PsychoGenics.
• The company entered into a Membership Interest Purchase Agreement to acquire Alpha-5 Integrin, LLC. Prof. Lawrence Steinman, the company's Executive Chairman and Co-Founder, was a 20% owner of Alpha-5 at the time of the transaction.
• The company has a consulting agreement with Prof. Lawrence Steinman, the company's Executive Chairman and Co-Founder, for which he receives $25,000 per quarter.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential future capital raises.
• Employees may experience uncertainty due to the company's financial challenges.
• Patients may benefit from the development of new therapies for CNS disorders and RASopathies.
• Suppliers and creditors may face increased risk due to the company's financial position.

Next Steps

• The company plans to continue the Phase 1 clinical trial of PAS-004.
• The company plans to advance PAS-004 into a Phase 1b/2 clinical trial for adult NF1-PN patients, followed by adolescent and pediatric patients.
• The company plans to continue the development of PAS-003 and PAS-001.
• The company plans to seek business development and collaborative opportunities for its discovery programs.

Key Dates

Keywords

PAS-004, MEK inhibitor, NF1-PN, clinical trials, biotechnology, CNS disorders, RASopathies, ALS, schizophrenia, drug development